Finanzen von Generation Bio Inc (GBIO)GBIOGeneration Bio Inc

Evaluating the bottom line, Generation Bio Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2019.95%, while the net margin is -346.30%. These profitability ratios, combined with a Return on Equity (ROE) of -80.81%, provide a clear picture of how effectively GBIO converts its operational activities into shareholder value.

In the context of the broader market, GBIO competes directly with industry leaders such as ATNM and RNXT. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, GBIO's gross margin of 100.00% stands against ATNM's 100.00% and RNXT's 84.27%. Such benchmarking helps identify whether Generation Bio Inc is trading at a premium or discount relative to its financial performance.

- Latest quarter provided: **2025/Q3**.

- Revenue: 1.594M, down **-78.90% YoY** (sharp top-line contraction).

- Net income: -5.52M (loss), **-63.95% YoY** (loss magnitude improved vs prior year, but still negative).

- EPS: -0.82, **-64.19% YoY** (improved vs prior year but still deeply negative).

- Gross margin: 100 (flat YoY), not enough to offset the steep revenue decline.

- Overall: fundamentals remain weak; current trading is better explained by corporate action expectations than by operating momentum.